Tegoprazan
As of the edition of 20 October 2026, Tegoprazan is a small molecule: in active development; acts on ATP4A and ATP4B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 56, 0 stopped early
- Disease areas
- Digestive system; Heart and blood vessels; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 1 | 1 | 0 |
| Phase 1 | 24 | 17 | 1 | 0 |
| Phase 2 | 3 | 1 | 1 | 0 |
| Phase 3 | 15 | 13 | 2 | 0 |
| Phase 4 | 10 | 3 | 5 | 0 |
| All trials | 56 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| HK inno.N | Lead sponsor of trials | 2011 to now |
| Shandong Luoxin Pharmaceutical Group Stock | Lead sponsor of trials | 2018 to now |
| Carnot | Lead sponsor of trials | 2024 to now |